MDX-1401: Preliminary Phase I data

Preliminary data from 12 evaluable patients in an ongoing, open-label, dose-escalation Phase I trial showed that 0.01-1 mg/kg once-weekly IV MDX-1401 showed that 8 patients had stable disease, with 2 ...